LINC00337 Induces Tumor Development and Chemoresistance to Paclitaxel of Breast Cancer by Recruiting M2 Tumor-Associated Macrophages

Investigators focused on the potential involvement and mechanism of LINC00337 in breast cancer (BCa). High-expressed LINC00337 accelerated viability and proliferation of BCa cells, improved the resistance of BCa cells to paclitaxel, and accelerated tumor growth.